Navigation Links
BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
Date:5/8/2009

BIRMINGHAM, Ala., May 8 /PRNewswire-FirstCall/ -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that, based on discussions with the U.S. Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS-BARDA), it is preparing a portion of its inventory of finished peramivir for addition to the U.S. Centers for Disease Control and Prevention (CDC) Strategic National Stockpile. This inventory is sufficient for the treatment of approximately one thousand patients and will be delivered in the event that the government so instructs. Intravenous (i.v.) peramivir is currently undergoing a pre-emergency use authorization (EUA) review. Government agencies are considering the future option of providing peramivir through an EUA in the event of a severe influenza outbreak with significant hospitalizations. BioCryst is advancing the clinical development of peramivir under terms of a $102.6 million, four-year contract from the HHS.

"BioCryst is working diligently with government agencies to provide i.v. peramivir as a treatment option for an influenza emergency," said Jon P. Stonehouse, President and Chief Executive Officer of BioCryst. "With its parenteral route of administration, peramivir has the potential to help patients who may have difficulty with an oral or inhaled anti-viral medication. In addition, BioCryst is in negotiations with the Division of Microbiology and Infectious Diseases (DMID) and the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH) to conduct a study of peramivir in a pediatric patient population."

The clinical activity of peramivir has previously been demonstrated in various clinical studies. The sensitivity of the swine flu virus to peramivir has recently been reported by the CDC (1). Ten of the thirteen isol
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. BioCryst Pharmaceuticals to Announce Peramivir Update and First Quarter 2009 Financial Results on May 8, 2009
2. BioCryst Reports Positive Preliminary Results of a Shionogi & Co., Ltd. Sponsored Phase II Study of I.V. Peramivir for the Treatment of Influenza in the Outpatient Setting
3. BioCryst Announces Initiation of Phase II Study of Intramuscular Peramivir for the Treatment of Seasonal Influenza
4. BioCryst Updates Peramivir Clinical Development Plan
5. BioCryst Provides Forodesine HCl Update
6. BioCryst Initiates Enrollment in Pivotal Trial of Forodesine HCL in Patients with Cutaneous T-Cell Lymphoma (CTCL)
7. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
8. USAID Provides $5M in Emergency Support as Swine Flu Spreads
9. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
10. Strativa Pharmaceuticals Provides Product Pipeline Update
11. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... OAKS, Calif. , May 23, 2013 Amgen ... Bank 38 th Annual  Healthcare Conference on Thursday, May ... Boston , beginning at 9:20 a.m. Eastern Daylight Time. ... Relations at Amgen, will present at the conference. Live audio ... on Amgen,s website, www.amgen.com , under Investors. A replay ...
(Date:5/23/2013)... , May 23, 2013 Nephros, Inc. (OTC ... medical device company that develops and sells high performance ... its rights offering.  In addition, the concurrent temporary reduction ... expired on May 17, 2013. Nephros estimates ... from the rights offering.   A portion of the proceeds ...
(Date:5/23/2013)... May 23, 2013  MGC Diagnostics Corporation (NASDAQ: ... technology company, today scheduled a conference call to discuss ... year 2013, ended April 30, 2013. The call will ... 2013. The Company will report financial results for the ... close on Thursday, May 30, 2013. ...
Breaking Medicine Technology:Nephros Announces Completion of Rights Offering 2Nephros Announces Completion of Rights Offering 3Nephros Announces Completion of Rights Offering 4MGC Diagnostics Corporation to Report Second Quarter Fiscal 2013 Financial Results on Thursday, May 30, 2013 2
... Arcion Therapeutics , a venture backed clinical ... today announced top-line results from a successful Phase 2b ... pain candidate, ARC-4558, in adult patients with painful diabetic ... 2 meeting with the United States Food and Drug ...
... , July 20 Allscripts (Nasdaq: ... selected the Allscripts Community Solution to power Huntington Health ... other health care providers across the San Gabriel Valley to connect ... where they are located or which clinical technologies they use. ...
Cached Medicine Technology:Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN) 2Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN) 3Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN) 4Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 2Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 3Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 4Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 5Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 6Huntington Memorial Hospital Selects Allscripts Community Solution to Create a Connected, Collaborative Health Community 7
(Date:5/25/2013)... (PRWEB) May 25, 2013 Communities of ... Texas. It is the fifth largest media market in the ... the number one visitor destination in Texas and a major ... to the American West as it is home to many ... will enjoy from sports to the arts. Residents and locals ...
(Date:5/25/2013)... SATURDAY, May 25 (HealthDay News) -- Many viruses and ... rabies and leptospirosis -- a bacteria-borne illness than can ... lurking at dog parks, according to a veterinarian. ... water and even the air, said Dr. Susan Nelson, ... Health Center. "Many of these serious diseases can be ...
(Date:5/25/2013)... States (PRWEB) May 25, 2013 ... largest underground shelter company in the US and ... underground structures for over 35 years. M.E. and ... U.S. Handbook of NBC Weapon Fundamentals and Shelter ... United States’ bible on shelter engineering. McCarthy is ...
(Date:5/25/2013)... May 25, 2013 Absolute Surgical Specialists, serving ... of the NALA’s businesses throughout the country participating in Shop ... participate in the nationwide event as he understands what military ... in the Army. He said, “I wanted to give something ... serve, but I live here too.” , Shop Local for ...
(Date:5/25/2013)... NY (PRWEB) May 25, 2013 ... problems, ranging from irritable bowel syndrome (IBS) to ... are among the most long-lasting, embarrassing, frustrating and ... natural foods for digestive health have provided ... there are many factors contributing to digestive health ...
Breaking Medicine News(10 mins):Health News:Communities of Distinction TV Presents May Air Dates for Dallas-Ft. Worth, Texas 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Dr. Craig Amshel of Absolute Surgical Specialists Offering Bowel Prep During the Shop Local for a Cause Event 2Health News:Natural Foods For Digestive Health Report and Video Published by BetterDigestion.org 2
... Pa., Jan. 14 Three Rivers,Pharmaceuticals, LLC finalized ... Pharmaceuticals International (NYSE: VRX ). Valeant is,receiving ... "Adding Infergen to our growing portfolio is ... president and chief executive,officer. "This purchase is only ...
... GREEN BAY, Wis., Jan. 14 Shopko announced plans to ... corner of Broadway and,Dousman Street in downtown Green Bay. The ... that will be the first,major anchor in the 90 million ... is expected to open in fall of 2008., "This ...
... Join Forces to Escape the Mistaken ... Label of Pornography, HOLLYWOOD, ... the promotion of sensual products, sexual education and,relationship improvement is set to ... and singles with seminars and,products to enhance their love lives in a ...
... Forest Hospital,Foundation board of directors presented a merger proposal ... care system for northeastern Illinois,and the surrounding region. The ... hospital boards and would bring together the clinical,strength and ... County.*, As part of the proposal, the Lake ...
... with serious risks, FDA notes , , MONDAY, Jan. 14 (HealthDay ... sclerosis, may also be used for patients with a moderate ... U.S. Food and Drug Administration announced Monday. , But the ... a potentially deadly brain infection, as well as other side ...
... of Illinois have found a simple solution to a problem ... buffers used to maintain the pH of laboratory samples to ... team, headed by chemistry professor Yi Lu, developed a method ... a range of low temperatures. , The study appears this ...
Cached Medicine News:Health News:Three Rivers Pharmaceuticals(R), LLC Acquires Hepatitis C Drug Infergen(R) from Valeant Pharmaceuticals 2Health News:Shopko Express Coming to Downtown Green Bay 2Health News:The First Annual LOVE L.A. Show Promotes Sensuality, Relationships and Sexual Education 2Health News:Lake Forest Hospital Proposes a New Health Care System in Lake County 2Health News:MS Drug Tysabri Approved for Crohn's Disease 2Health News:MS Drug Tysabri Approved for Crohn's Disease 3Health News:New buffer resists pH change, even as temperature drops 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: